Cytodyn Inc (CYDY)

OTC Markets
2.2850
-0.0350(-1.51%)
After Hours
2.2800
-0.0100(-0.4367%)
- Delayed Data
  • Volume:
    1,305,576
  • Bid/Ask:
    0.0000/0.0000
  • Day's Range:
    2.2600 - 2.4300

CYDY Overview

Prev. Close
2.32
Day's Range
2.26-2.43
Revenue
-
Open
2.31
52 wk Range
1.25-7.4
EPS
-0.27
Volume
1,305,576
Market Cap
1.47B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
2,170,270
P/E Ratio
-
Beta
-0.8
1-Year Change
-32.05%
Shares Outstanding
644,807,308
Next Earnings Date
Nov 03, 2021
What is your sentiment on Cytodyn Inc?
or
Market is currently closed. Voting is open during market hours.

Cytodyn Inc News

  • Key events next week - healthcare
    • BySeeking Alpha-

    Noteworthy events during the week of June 3 - 9 for healthcare investors.Sunday (6/3): Associated Professional Sleep Societies Annual Meeting (SLEEP), Baltimore, MD (4 days). Jazz...

Cytodyn Inc Analysis

  • 7 Stocks That Could Jump Higher

    1. The Boeing CompanyBoeing (NYSE:BA), on the 737 MAX testing on Monday, popped out of a wedge and jumped 24.48, or 14.4%, to 194.49, just a penny off the session high at 194.50,...

  • 6 Stocks That Could Edge Higher

    1.Allied Healthcare ProductsAllied Healthcare Products (NASDAQ:AHPI) popped, pulled back, reversed on Tuesday, and on Wednesday it followed through, jumping 1.54, or 13%, to...

  • 6 Stocks With More Room To Run

    1. Alpha Pro TechAlpha Pro Tech (NYSE:APT) jumped 1.87, or 12%, to 17.48, on 10.8 million shares traded on Tuesday. This stock took off and has been running up the channel for...

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellNeutralNeutralBuyBuy
Technical IndicatorsStrong SellBuySellStrong BuySell
SummaryStrong SellNeutralNeutralStrong BuyNeutral

Cytodyn Inc Company Profile

Cytodyn Inc Company Profile

Employees
24

CytoDyn Inc. is a clinical-stage biotechnology company. The Company is focused on the clinical development and commercialization of humanized monoclonal antibodies to treat Human Immunodeficiency Virus (HIV) infection. The Company's lead product candidate, PRO 140, belongs to a class of HIV therapies known as entry inhibitors that block HIV from entering into and infecting certain cells. The Company's product pipeline also includes Cytolin and CytoFeline. Cytolin is a mouse monoclonal antibody developed to identify a specific type of immune cell called a cytotoxic T cell, or cytotoxic T lymphocyte (CTL). CytoFeline is an anti-lymphocyte function-associated antigen-1 (LFA-1) antibody for the treatment of Feline Immunodeficiency Virus (FIV) infection. PRO 140 blocks HIV from entering a cell by binding to a molecule called C-C chemokine receptor type 5 (CCR5). The Company has finished Phase II clinical trials for PRO 140 with demonstrated antiviral activity in man.

Read More
  • CytoDyn’s Final mTNBC Report Indicates as Much as 980% Increase in 12-Month Overall Survival and Up to 660% in 12-Month Modified Progression Free Survival
    0
    • CytoDyn's Vyrologix Shortens Hospital Stays, Improves Survival in Severe COVID-19 | BioSpace ...In a subset of critical patients
      1
      • it has huge potential, these are bargain Price's
        2
        • it has huge potential, these are bargain Price's
          2
          • 🆙️🆙️🆙️
            1
            • this will ***after new year
              0
              • will this do anything
                0
                • I believe so lets be patience
                  0
              • News?
                1
                • CytoDyn on go with UK late-stage study of leronlimab for COVID-19 https://seekingalpha.com/news/3607345
                  0
                  • tomorrow night at share holders meeting.
                    0
                    • Remember to wear a mask.
                      0
                  • Results are out- why the drop?
                    0
                    • They didn't release full results. It is better then remdesivir that's for sure.
                      2
                  • the results come tomorrow!!!!!
                    1
                    • Filled with NASDAQ today.
                      0
                      • Why did the CEO liquidate 15 million dollars worth of stock on may 20th 2020? This company has raised money for over a decade, for HIV, now carona related trends. But has failed to ever generate a single revenue dollar in a decade of existence. 85% of the float is held by the retail investor who buys into these hyped up attachemts. Insiders are selling faster than I can type this *** I dont care how high this rubbish goes. Biotechs like this remind me of gold miners of the 2000s. Raise money, pay yourself a handsome salary, dig, find nothing. Repeat. A decade of asset destruction.
                        8
                        • Jarrod Segurahow is your bet going? You can report all my comments. I come back here routinely to enjoy your salt.
                          0
                        • Jarrod Segurayou need shelter and/or food yet? Lol
                          0
                        • Hows everyone doing st $1.69 a share? 🤣😂
                          0
                      • Buy below 3
                        1
                        • cydy is now at a decent entry point from it's highs. covid therapy would be nice, but the prize is hiv by early 2021. Will go to 16. Do not be fooled by shorts. This is a risky stock and nothing the shorts said changes the bull thesis. Who wears short, shorts...lol Ask Elon.
                          2
                          • Lol. They have 10 employees with a market cap of $3B. Nah. Think I’ll pass. Only analyst is a short seller vampire. This belongs on the pink sheets for a reason. If they were a respectable company they wouldn’t change their name ever 2 years, hire on 5 C suite execs 2 months ago and the CEO wouldn’t be cashing $15M worth of stock and distributing stock like candy to be sold. File for the nasdaq and then I’ll take this company serious.
                            1
                          • William Gutierrezcouldnt agree more mate
                            1
                        • Definitely could be a game changer for fighting the virus.
                          1
                          • https://stockhouse.com/news/press-releases/2020/06/30/shareholder-alert-block-leviton-llp-investigating-cytodyn-inc-for-possible CEO SOLD $30 million in stock @$3, under investigation for securities fraud. Be careful.
                            4
                            • Looking to launch in Mexico. Buy pullback to 3
                              1
                              • stock is fairly priced till covid trial results, and hiv fda approval. stock took hit based on citron report. Edward left of citron is a short seller and imo a con man. He's been banned from some markets. cydy is risky but ignore shorts. they profit when you panic. Look what short sellers tried to do to tesla. Luckily, they lost billions! 😀
                                0
                                • Bullish oppurtunity to buy cheap. As soon as company clears up the confussion it will go right back up.
                                  2
                                  • Buy while you can. On sale!
                                    0
                                    • loss of steam ? flush ? manipulation ? what the world happen today ?
                                      0
                                      • why is this happening?
                                        0
                                        • why do u like this particular company so much?
                                          0
                                        • read this article http://leronlimab.news/
                                          2
                                        • lol
                                          0
                                      • :( I can't access otc
                                        0
                                        Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                                        Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.